Serán BioScience, a US-based contract development and manufacturing organisation (CDMO), has secured more than $200m in strategic growth financing, led by Bain Capital Life Sciences.
Existing investor Vivo Capital, a US-based investment firm focused on healthcare and biotechnology industries, also participated in the financing.
Serán is engaged in providing a comprehensive range of development, analytical and manufacturing services to pharmaceutical and biotechnology companies.
The company will use the financing to build a new commercial-scale manufacturing facility.
The new facility would help Serán support its continued growth by providing integrated capabilities across multiple drug delivery and final dose formats.
It will also enable the company to provide advanced solutions for clients, from early development to commercial supply.
Bain Capital managing director Will Cozean said: “We are impressed with Serán’s differentiated expertise and capabilities in drug development and clinical manufacturing.
“We believe the Company is well-positioned to benefit from long-term secular tailwinds given the importance of drug delivery technology to help address increasing challenges facing next-generation oral drugs.
“We look forward to an impactful partnership and to leveraging our experience and resources to build and scale Serán into a true end-to-end provider of manufacturing services for complex drug products.”
Serán plans to build the commercial manufacturing facility in a 200,0000ft2 campus in Bend, Oregon, which is expected to be completed in 2026.
The new facility will support oral, pulmonary, and nasal delivery modalities, along with particle engineering solutions such as spray drying, hot melt extrusion, nano-milling, and fluid-bed manufacturing.
It will also support comprehensive finished dose capabilities, including granulation, tabletting, coating, encapsulation, and powder filling, along with modified-release products.
An adjacent facility, which is already under construction, will enable extensive packaging, labelling, serialisation, and distribution capabilities, said Serán.
Serán co-founder and CEO Dan Smithey said: “This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity.
“We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines.”
